Skip to main content
. 2010 Oct 19;103(10):1510–1517. doi: 10.1038/sj.bjc.6605944

Table 3. Associations between HPV status and risk of recurrence, event and/or death.

Treatment group
  All (n=195)
Surgery alone (n=14)
Surgery with adjuvant radiotherapy (n=110)
Definitive radiotherapy alone (n=24)
Definitive radiotherapy and chemotherapy (n=47)
  HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Loco-regional recurrence
Univariate
  HPV
   Negative 1.0   1.0   1.0   1.0   1.0  
   Positive 0.34 (0.17, 0.61) 0.0002 0.71 (0.04, 5.57) 0.8 0.38 (0.14, 0.91) 0.03 0.18 (0.03, 0.75) 0.02 0.36 (0.10, 1.03) 0.06
Adjusted
  HPV
   Negative 1.0       1.0   1.0   1.0  
   Positive 0.27 (0.13, 0.52)a <0.0001 Not estimatedb   0.30 (0.10, 0.82)c 0.02 0.12 (0.01, 0.61)d 0.009 0.25 (0.06, 0.79)c 0.02
                     
Event-free survival
Univariate
  HPV                    
   Negative 1.0   1.0   1.0   1.0   1.0  
   Positive 0.31 (0.19, 0.49) <0.0001 0.50 (0.07, 2.10) 0.4 0.28 (0.13, 0.53) <0.0001 0.19 (0.04, 0.60) 0.004 0.46 (0.19, 1.03) 0.06
Adjusted
  HPV                    
   Negative 1.0       1.0   1.0   1.0  
   Positive 0.23 (0.14, 0.39)a <0.0001 Not estimatedb   0.19 (0.08, 0.40)c <0.0001 0.14 (0.02, 0.54)d 0.003 0.36 (0.14, 0.85)c 0.02
                     
Overall survival
Univariate
  HPV                    
   Negative 1.0   1.0   1.0   1.0   1.0  
   Positive 0.29 (0.17, 0.48) <0.0001 0.98 (0.14, 4.57) 1.0 0.18 (0.07, 0.40) <0.0001 0.24 (0.05, 0.82) 0.02 0.43 (0.17, 0.99) 0.05
Adjusted
  HPV                    
   Negative 1.0       1.0   1.0   1.0  
   Positive 0.24 (0.13, 0.42)a <0.0001 Not estimatedb   0.11 (0.04, 0.28)c <0.0001 0.11 (0.01, 0.52)d 0.004 0.37 (0.13, 0.90)c 0.03

Abbreviations: HPV=human papillomavirus; HR=hazard ratio; CI=confidence interval; RT=radiation therapy; CT=chemotherapy.

a

Adjusted for age, gender, tumour grade, tumour stage, primary site and treatment.

b

Multivariable analyses not carried out owing to small numbers.

c

Adjusted for age, gender, tumour grade, tumour stage and primary site.

d

Adjusted for age, tumour grade and tumour stage; gender and primary site not adjusted owing to categories with low numbers of events.